CrystalGenomics Applies for Early Termination of Domestic Phase 2 Trial for COVID-19 Treatment

[Asia Economy Reporter Myunghwan Lee] CrystalGenomics announced on the 1st that it has applied for early termination of the Phase 2 clinical trial plan evaluating the efficacy and safety of 'Camostat,' a COVID-19 treatment candidate.

Regarding the reason for early termination, CrystalGenomics explained, "Due to the global spread of Omicron subvariants and the expansion of vaccine prescriptions, the transition to endemic (periodic outbreak of infectious diseases) is rapidly progressing, making it difficult to recruit clinical trial patients," adding, "With the entry into the COVID endemic phase, regulatory authorities are also discontinuing 'fast-track' procedures such as emergency approvals."